Merck sells eye business

First Merck sold its consumer business to Bayer. Now, it's also (almost) getting out of the eye-care business. The company announced Tuesday that it has sold part of the business to Santen Pharmaceutical.

The $600-million-plus-milestones deal includes rights to the eye products Cosop, Trusop and Timoptic in Japan and “key markets in Europe and Asia Pacific.” Merck said the sales for these products in these territories is around $400 million a year.

Merck will continue to sell these products in Latin America, Canada and Australia, but sold US rights to Akorn in 2013 and 2014.

You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.